OPKO Health Inc
XMUN:XCY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
OPKO Health Inc
XMUN:XCY
|
US |
|
E
|
Electricity Generating PCL
SET:EGCO
|
TH |
|
Electricity Generating PCL
OTC:EYUBY
|
TH |
OPKO Health Inc
OPKO Health is a healthcare company that makes money in two main ways: it runs clinical laboratory and diagnostic testing services, and it develops and sells prescription medicines. Its lab business provides blood and other tests that doctors and hospitals use to diagnose and monitor disease. Its pharmaceutical business sells approved drugs and also works on developing new treatments. The company’s main customers are doctors, hospitals, healthcare providers, patients, and sometimes other drug companies that license its products or research. OPKO earns revenue when its labs process tests, when its medicines are prescribed and sold, and when it receives licensing or collaboration payments tied to its drug programs. What makes OPKO different is that it sits in both the diagnostics and drug-development parts of healthcare. Many biotech companies only chase new medicines, while many lab companies only run testing services. OPKO combines both, which gives it more than one way to serve the healthcare system and more than one source of business.
OPKO Health is a healthcare company that makes money in two main ways: it runs clinical laboratory and diagnostic testing services, and it develops and sells prescription medicines. Its lab business provides blood and other tests that doctors and hospitals use to diagnose and monitor disease. Its pharmaceutical business sells approved drugs and also works on developing new treatments.
The company’s main customers are doctors, hospitals, healthcare providers, patients, and sometimes other drug companies that license its products or research. OPKO earns revenue when its labs process tests, when its medicines are prescribed and sold, and when it receives licensing or collaboration payments tied to its drug programs.
What makes OPKO different is that it sits in both the diagnostics and drug-development parts of healthcare. Many biotech companies only chase new medicines, while many lab companies only run testing services. OPKO combines both, which gives it more than one way to serve the healthcare system and more than one source of business.
Revenue: OPKO reported Q2 2026 revenue of $163.6 million, up from $156.8 million a year ago, while net loss improved sharply to $8.4 million, or $0.01 per share.
Guidance: Full-year 2026 revenue guidance was raised to $560 million to $585 million, even as total costs and expenses were lowered to $710 million to $740 million.
Diagnostics: Diagnostics revenue fell year over year to $74.5 million, but the business swung to $4.8 million of operating income, helped by the Labcorp transaction and a more focused cost base.
Pharma: Pharmaceutical revenue rose to $89 million, supported by stronger international sales, RAYALDEE cash flow, Pfizer profit share, BARDA funding, and $29.4 million from Nicoya preferred shares.
Pipeline: Management highlighted steady progress across ModeX, the GLP-1/glucagon program, oral PTH, and the growth hormone antagonist, while also signaling an in vivo CAR-T start by late 2026 or early 2027.
Cash Return: The company ended the quarter with over $300 million in cash and repurchased 9.7 million shares for about $13 million, with about $94 million still authorized for buybacks.
